



General description

Cyclophosphamide is an antineoplastic alkylating agent, used in the treatment of many cancers.

| | |
|--------------------|---|
| INN | Cyclophosphamide |
| ATC codes | L01AA01 |
| Medicine type | Chemical agent |
| EML status history | <p>First added in 1977 (TRS 615) for Diffuse large B-cell lymphomas</p> <p>Added in 1977 (TRS 615) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma</p> <p>Added in 1977 (TRS 615) for Malignant neoplasms of breast</p> <p>Added in 1977 (TRS 615) for Malignant trophoblastic neoplasms of placenta</p> <p>Added in 1977 (TRS 615) for Follicular lymphoma</p> <p>Added in 1977 (TRS 615) for Other specified malignant neoplasms of breast</p> <p>Added in 1977 (TRS 615) for Hodgkin lymphoma</p> <p>Added in 1977 (TRS 615) for Rhabdomyosarcoma primary site</p> <p>Added in 1977 (TRS 615) for Burkitt lymphoma including Burkitt leukaemia</p> <p>Added in 1977 (TRS 615) for Lymphoid leukaemia, not elsewhere classified</p> <p>Added in 1977 (TRS 615) for Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2019 (TRS 1021) for Plasma cell myeloma</p> <p>Added in 2021 (TRS 1035) for Other specified gliomas of brain</p> <p>Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis</p> <p>Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive</p> <p>Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative</p> |
| Wikipedia | Cyclophosphamide |
| DrugBank | Cyclophosphamide |

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Indications

Diffuse large B-cell lymphomas

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Other specified malignant neoplasms of breast

Hodgkin lymphoma

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Other specified gliomas of brain

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

